Advancing cell wall inhibitors towards clinical applications.
about
Dalbavancin for the treatment of paediatric infectious diseases.Mechanistic Understanding of Lanthipeptide Biosynthetic Enzymes.Ribosomal Natural Products, Tailored To Fit.Two Flavoenzymes Catalyze the Post-Translational Generation of 5-Chlorotryptophan and 2-Aminovinyl-Cysteine during NAI-107 Biosynthesis.Expanding the potential of NAI-107 for treating serious ESKAPE pathogens: synergistic combinations against Gram-negatives and bactericidal activity against non-dividing cells.Gifted microbes for genome mining and natural product discovery.Complex Regulatory Networks Governing Production of the Glycopeptide A40926.
P2860
Q38937430-66C6011F-9D28-4302-A83E-E7AC62631406Q39109460-A39A2D66-AA52-45C8-BB02-909B8C72919EQ47953416-56F852DE-4A1B-47B9-9B2D-0F18AC3A02AEQ48108610-61A33F3D-966A-4561-A182-441F257AA96BQ50221694-22DA665E-7CCB-4A66-B7E3-9E2DFED97FAAQ50529262-5BD5E5B2-8FFF-4D9A-832C-9A8F921D6EAFQ52331025-17DBB8D7-0F36-4D90-AD9C-726BC82E68F6
P2860
Advancing cell wall inhibitors towards clinical applications.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Advancing cell wall inhibitors towards clinical applications.
@en
type
label
Advancing cell wall inhibitors towards clinical applications.
@en
prefLabel
Advancing cell wall inhibitors towards clinical applications.
@en
P2093
P2860
P1476
Advancing cell wall inhibitors towards clinical applications.
@en
P2093
João C S Cruz
Paolo Monciardini
Sonia I Maffioli
Stefano Donadio
P2860
P304
P356
10.1007/S10295-015-1703-9
P577
2015-10-29T00:00:00Z